Epitope mapping of full-length glycoprotein D from HSV-2 reveals a novel CD4+ CTL epitope located at the transmembrane-cytoplasmic junction

Cellular Immunology

Volumn 239, Issue 2, 2006, Pages 113-120

  Cooper, David ^a   Mester, Joseph C ^a   Guo, Min ^a   Nasar, Farooq ^a   Souza, Victor ^a   Dispoto, Sharon ^a   Sidhu, Maninder ^a   Hagen, Michael ^a   Eldridge, John H ^a   Natuk, Robert J ^a   Pride, Michael W ^a  

^a WYETH RESEARCH   (United States)

Author keywords

Epitope; Glycoprotein D; Herpes simplex virus; IL 12; Immunodominance; Vaccine

Indexed keywords

ALUMINUM PHOSPHATE; ASPARAGINYLCYSTEINYLALANYLISOLEUCYLPROLYLISOLEUCYLTHREONYLVALYLMETHIONYL GLUTAMYLTYROSYLTHREONYLGLUTAMYLCYSTEINYLPROLINE; EPITOPE; GAMMA INTERFERON; GLUTAMINYLPROLYLPROLYLSERYLISOLEUCYLPROLYLISOLEUCYLTHREONYLVALYLTYROSYL TYROSYLALANYLVALYLLEUCYLGLUTAMIC ACID; GLYCOPROTEIN D; GLYCYLISOLEUCYLALANYLPHENYLALANYLTRYPTOPHANYLVALYLARGINYLARGINYLARGINYL ALANYLGLUTAMINYLMETHIONYLALANYLPROLYLLYSINE; HERPES SIMPLEX VACCINE; INTERLEUKIN 12; LYSYLPROLYLPROLYLTYROSYLTHREONYLSERYLTHREONYLLEUCYLLEUCYLPROLYLPROLYL GLUTAMYLLEUCYLSERYLASPARTYL; T LYMPHOCYTE ANTIGEN; THREONYLVALYLSERYLSERYLGLUTAMINYLISOLEUCYLPROLYLPROLYLASPARAGINYL TRYPTOPHANYLHISTIDYLISOLEUCYLPROLYLSERYLISOLEUCYL; TRYPTOPHANYLTHREONYLGLUTAMYLISOLEUCYLTHREONYLGLUTAMINYLPHENYLALANYL ISOLEUCYLLEUCYLGLUTAMYLHISTIDYLARGINYLALANYLARGINYLALANINE; UNCLASSIFIED DRUG; VIRUS VECTOR;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL JUNCTION; CELL SPECIFICITY; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG BINDING; DRUG DESIGN; EPITOPE MAPPING; EXTRACELLULAR SPACE; FEMALE; HERPES SIMPLEX VIRUS 2; IMMUNIZATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; SPLEEN CELL; STRUCTURE ANALYSIS;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD4; CELL MEMBRANE; CERCOPITHECUS AETHIOPS; CHO CELLS; CRICETINAE; CRICETULUS; CYTOPLASM; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; FEMALE; HERPESVIRUS 2, HUMAN; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; VERO CELLS; VIRAL ENVELOPE PROTEINS;

HERPES; HUMAN HERPESVIRUS 2;

EID: 33745825127     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2006.04.005     Document Type: Article

References (31)

1. Corey L. Challenges in genital herpes simplex virus management. J. Infect. Dis. 186 Suppl. 1 (2002) S29-S33
2. Koelle D.M., and Corey L. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin. Microbiol. Rev. 16 (2003) 96-113
3. Highlander S.L., Sutherland S.L., Gage P.J., Johnson D.C., Levine M., and Glorioso J.C. Neutralizing monoclonal antibodies specific for herpes simplex virus glycoprotein D inhibit virus penetration. J. Virol. 61 (1987) 3356-3364
4. Fuller A.O., and Spear P.G. Anti-glycoprotein D antibodies that permit adsorption but block infection by herpes simplex virus 1 prevent virion-cell fusion at the cell surface. Proc. Natl. Acad. Sci. USA 84 (1987) 5454-5458
5. Corey L., Langenberg A.G., Ashley R., Sekulovich R.E., Izu A.E., Douglas Jr. J.M., Handsfield H.H., Warren T., Marr L., Tyring S., DiCarlo R., Adimora A.A., Leone P., Dekker C.L., Burke R.L., Leong W.P., and Straus S.E. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 282 (1999) 331-340
6. Stanberry L.R., Spruance S.L., Cunningham A.L., Bernstein D.I., Mindel A., Sacks S., Tyring S., Aoki F.Y., Slaoui M., Denis M., Vandepapeliere P., and Dubin G. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347 (2002) 1652-1661
7. Long D., Madara T.J., Ponce de Leon M., Cohen G.H., Montgomery P.C., and Eisenberg R.J. Glycoprotein D protects mice against lethal challenge with herpes simplex virus types 1 and 2. Infect. Immun. 43 (1984) 761-764
8. Landolfi V., Zarley C.D., Abramovitz A.S., Figueroa N., Wu S.L., Blasiak M., Ishizaka S.T., and Mishkin E.M. Baculovirus-expressed herpes simplex virus type 2 glycoprotein D is immunogenic and protective against lethal HSV challenge. Vaccine 11 (1993) 407-414
9. Mishkin E.M., Fahey J.R., Kino Y., Klein R.J., Abramovitz A.S., and Mento S.J. Native herpes simplex virus glycoprotein D vaccine: immunogenicity and protection in animal models. Vaccine 9 (1991) 147-153
10. + CTL responses. Vaccine 23 (2004) 236-246
11. Schmid D.S., and Rouse B.T. The role of T cell immunity in control of herpes simplex virus. Curr. Top. Microbiol. Immunol. 179 (1992) 57-74
12. Grammer S.F., Sette A., Colon S., Walker L., and Chesnut R. Identification of an HSV-1/HSV-2 cross-reactive T cell determinant. J. Immunol. 145 (1990) 2249-2253
13. Yamashita K., and Heber-Katz E. Lack of immunodominance in the T cell response to herpes simplex virus glycoprotein D after administration of infectious virus. J. Exp. Med. 170 (1989) 997-1002
14. Eberl G., Kessler B., Eberl L.P., Brunda M.J., Valmori D., and Corradin G. Immunodominance of cytotoxic T lymphocyte epitopes co-injected in vivo and modulation by interleukin-12. Eur. J. Immunol. 26 (1996) 2709-2716
15. Gately M.K., Warrier R.R., Honasoge S., Carvajal D.M., Faherty D.A., Connaughton S.E., Anderson T.D., Sarmiento U., Hubbard B.R., and Murphy M. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo. Int. Immunol. 6 (1994) 157-167
16. Vasilakis N., Falvey D., Gangolli S.S., Coleman J., Kowalski J., Udem S.A., Zamb T.J., and Kovacs G.R. Transfection-independent production of alphavirus replicon particles based on poxvirus expression vectors. Nat. Biotechnol. 21 (2003) 932-935
17. Gangolli S.S., Vasilakis N., Kovacs G.R., Zamb T.J., and Kowalski J. A method of alphavirus replicon particle titration based on expression of functional replicase/transcriptase. J. Virol. Methods 109 (2003) 133-138
18. Meseda C.A., Elkins K.L., Merchlinsky M.J., and Weir J.P. Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone. J. Infect. Dis. 186 (2002) 1065-1073
19. Muggeridge M.I., Wilcox W.C., Cohen G.H., and Eisenberg R.J. Identification of a site on herpes simplex virus type 1 glycoprotein D that is essential for infectivity. J. Virol. 64 (1990) 3617-3626
20. Huston J.S., Levinson D., Mudgett-Hunter M., Tai M.S., Novotny J., Margolies M.N., Ridge R.J., Bruccoleri R.E., Haber E., Crea R., et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA 85 (1988) 5879-5883
21. Velders M.P., McElhiney S., Cassetti M.C., Eiben G.L., Higgins T., Kovacs G.R., Elmishad A.G., Kast W.M., and Smith L.R. Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Res. 61 (2001) 7861-7867
22. BenMohamed L., Bertrand G., McNamara C.D., Gras-Masse H., Hammer J., Wechsler S.L., and Nesburn A.B. Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity. J. Virol. 77 (2003) 9463-9473
23. Heber-Katz E., Hollosi M., Dietzschold B., Hudecz F., and Fasman G.D. The T cell response to the glycoprotein D of the herpes simplex virus: the significance of antigen conformation. J. Immunol. 135 (1985) 1385-1390
24. Tuohy V.K., Yu M., Yin L., Mathisen P.M., Johnson J.M., and Kawczak J.A. Modulation of the IL-10/IL-12 cytokine circuit by interferon-beta inhibits the development of epitope spreading and disease progression in murine autoimmune encephalomyelitis. J. Neuroimmunol. 111 (2000) 55-63
25. Peter K., Men Y., Pantaleo G., Gander B., and Corradin G. Induction of a cytotoxic T-cell response to HIV-1 proteins with short synthetic peptides and human compatible adjuvants. Vaccine 19 (2001) 4121-4129
26. Katae M., Miyahira Y., Takeda K., Matsuda H., Yagita H., Okumura K., Takeuchi T., Kamiyama T., Ohwada A., Fukuchi Y., and Aoki T. Coadministration of an interleukin-12 gene and a Trypanosoma cruzi gene improves vaccine efficacy. Infect. Immun.70 (2002) 4833-4840
27. Lasarte J.J., Corrales F.J., Casares N., Lopez-Diaz de Cerio A., Qian C., Xie X., Borras-Cuesta F., and Prieto J. Different doses of adenoviral vector expressing IL-12 enhance or depress the immune response to a coadministered antigen: the role of nitric oxide. J. Immunol. 162 (1999) 5270-5277
28. Gherardi M.M., Ramirez J.C., and Esteban M. Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prim. J. Virol. 74 (2000) 6278-6286
29. Salem M.L., Kadima A.N., Zhou Y., Nguyen C.L., Rubinstein M.P., Demcheva M., Vournakis J.N., Cole D.J., and Gillanders W.E. Paracrine release of IL-12 stimulates IFN-gamma production and dramatically enhances the antigen-specific T cell response after vaccination with a novel peptide-based cancer vaccine. J. Immunol. 172 (2004) 5159-5167
30. Grohmann U., Belladonna M.L., Bianchi R., Orabona C., Ayroldi E., Fioretti M.C., and Puccetti P. IL-12 acts directly on DC to promote nuclear localization of NF-kappaB and primes DC for IL-12 production. Immunity 9 (1998) 315-323
31. Langrish C.L., McKenzie B.S., Wilson N.J., de Waal Malefyt R., Kastelein R.A., and Cua D.J. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol. Rev. 202 (2004) 96-105